Another innovation with Juvederm Voluma™ XC is its use of Allergan's proprietary VYCROSS™ technology, an advanced manufacturing process that results in a smooth gel that flows easily and consistently. This unique formulation contributes to the lift capacity to correct volume loss in the cheek area and to the duration of the product.Additionally, Juvederm Voluma™ XC contains a small amount of lidocaine which helps to numb the treatment area during the injection procedure.
In a press release issued by Allergan®, Scott M. Whitcup, M.D., Executive Vice President, Research and Development, Chief Scientific Officer, Allergan, said, "Since 2002, Allergan has remained the leader in the medical aesthetics category as a result of our continued commitment to research and development, which has led to the approval of innovative products such as BOTOX® Cosmetic and JUVÉDERM® XC. We are pleased that the FDA has now approved Juvederm Voluma™ XC, the first product of its kind specifically formulated to correct age-related volume loss in the cheek area. Juvederm Voluma™XC represents the latest innovation in Allergan's growing portfolio of facial aesthetic products developed to address previously unmet patient needs."
“With aging the cheeks descend and the face becomes flat in the cheek area, and full and jowly along the jaw line,” explains Dr. Anne White, of Carolina Laser & Cosmetic Center, which opened in 2002. “We lose the beautiful inverted triangle of youth in the mid face. Now with Juvederm Voluma, my patients can finally get long lasting correction of volume depletion in the mid face, restoring the normal youthful proportions and that beautiful apple cheek that is so synonymous with beauty. Volumizing the mid face has the added benefit of lifting the lower face and jowls, smoothing away wrinkles and folds in the lower face, even without treating the folds around the mouth.”